Sage Science Review of Educational Technology
I18 - Health: Government Policy; Regulation; Public Health
C21 - Cross-Sectional Models; Spatial Models; Treatment Effect Models; Quantile Regressions
C52 - Model Evaluation, Validation, and Selection

The Impact of Pharmacovigilance Training Programs on Healthcare Professionals' Knowledge, Attitudes, and Practices in Developing Countries: A Study on MENA Countries

Zahra Lathifa
Helwan University
zehra@decabg.eu

Attia Aman-Ullah
Faculty of Management Sciences Preston University Islamabad, Pakistan

Abstract

Background: Pharmacovigilance is essential for ensuring the safety and efficacy of medicines. Healthcare professionals (HCPs) play a crucial role in identifying and reporting adverse drug reactions (ADRs) to regulatory authorities. However, their knowledge, attitudes, and practices (KAP) related to pharmacovigilance can vary depending on various factors.

Method: This study aimed to investigate the relationship between HCPs' KAP related to pharmacovigilance and independent variables such as education and training, access to information, perception of ADRs, time constraints, organizational support, fear of legal consequences, and language barriers. A linear regression model was used to analyze the data collected from a sample of HCPs.

Results: The results showed that all independent variables, excep t for language barriers and fear of legal consequences, were statistically significant in predicting KAP. The R-squared value of 0.855711 suggested that the model provided a good fit to the data and had a high degree of explanatory power. The mean KAP score was close to 3, and the standard deviation was relatively narrow. The F-statistic of 234.6801 and p-value of 0.000000 indicated that the model as a whole was statistically significant. The Durbin-Watson statistic of 1.834067 suggested that there was no significant autocorrelation in the residuals.

Conclusion: The study highlights the importance of education and training, access to information, perception of ADRs, time constraints, and organizational support in improving HCPs' KAP related to pharmacovigilance. Efforts should be made to address language barriers and alleviate the fear of legal consequences to further enhance HCPs' KAP. The study's findings could inform the development of targeted interventions and policies to improve pharmacovigilance practices and enhance patient safety.

Keywords:

1. *attitudes*
2. *healthcare professionals*
3. *knowledge*
4. *linear regression*
5. *pharmacovigilance*
6. *practices*

Date of Submission: March 14, 2022
Date of Peer Review: April 17, 2022
Date of Acceptance: July 19, 2022
Month of Publishing: July 2022
Financial or other competing interests: None

Introduction

Pharmacovigilance, which refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, is an essential component of healthcare systems worldwide [1], [2]. In developing countries, where access to medicines and healthcare resources may be limited, pharmacovigilance assumes even greater importance. In this context, pharmacovigilance training programs for healthcare professionals are crucial for improving the safety and quality of healthcare services [3], [4].

Pharmacovigilance is a crucial aspect of the healthcare industry that focuses on the detection, assessment, and prevention of adverse drug reactions (ADRs) and medication errors. It plays a critical role in ensuring patient safety by identifying potential risks associated with the use of medications, including prescription drugs, over-the-counter drugs, and herbal remedies. The importance of pharmacovigilance cannot be overemphasized, as it helps to monitor drug safety and minimize the risk of harm to patients [5], [6]. Pharmacovigilance involves the systematic collection, analysis, and reporting of adverse events related to medications, which enables regulatory agencies and healthcare professionals to make informed decisions about the safety and efficacy of drugs.

Pharmacovigilance also plays a significant role in post-marketing surveillance, which involves monitoring the safety of drugs after they have been approved for use [7]–[10]. This is important because some adverse reactions may only become apparent after a drug has been on the market for some time and used by a larger population [11]. By identifying these adverse reactions, pharmacovigilance can help to reduce the risk of harm to patients and improve the overall safety of drugs. In addition, pharmacovigilance helps to improve public confidence in drugs and the healthcare system by ensuring that drugs are safe and effective, which is essential for the success of any healthcare system.

The Need for Pharmacovigilance Training Programs in Developing Countries Developing countries face numerous challenges in ensuring the safety and efficacy of medicines. These include the lack of regulatory capacity, inadequate healthcare infrastructure, limited resources, and insufficient public awareness about drug safety. In such contexts, healthcare professionals play a critical role in identifying and reporting adverse drug reactions (ADRs), monitoring drug use, and promoting rational drug use. However, many healthcare professionals in developing countries may not have adequate knowledge or skills related to pharmacovigilance. They may not be aware of the importance of reporting ADRs, may lack training in recognizing and managing ADRs, or may have limited access to pharmacovigilance resources [12].

Pharmacovigilance training programs can address these challenges by providing healthcare professionals with the necessary knowledge, skills, and resources to effectively monitor and report ADRs. Such programs can help to raise awareness about drug safety issues, promote a culture of safety, and improve the quality of healthcare services. Moreover, pharmacovigilance training can enhance the credibility and reputation of healthcare professionals and healthcare facilities, thereby improving patient trust and satisfaction.

Pharmacovigilance training programs offer a range of benefits for healthcare professionals in developing countries. One of the primary benefits is improved knowledge and skills related to drug safety and ADR reporting. Healthcare professionals who undergo such training can gain a better understanding of drug safety issues, including the importance of reporting adverse events, and develop the necessary skills to identify and manage ADRs. This can result in more accurate and complete ADR reporting, leading to improved patient safety and better healthcare outcomes.

Another benefit of pharmacovigilance training programs is increased confidence among healthcare professionals in managing ADRs and reporting adverse events. When healthcare professionals are confident in their ability to identify and report ADRs, they are more likely to do so, which can help to improve the quality of healthcare services.

Pharmacovigilance training programs can also lead to better patient care. By promoting rational drug use and identifying potential safety issues, healthcare professionals who undergo such training can prevent harm to patients and improve healthcare outcomes. This can help to ensure that patients receive the best possible care, leading to greater patient satisfaction.

Finally, pharmacovigilance training programs can improve the performance of healthcare institutions. By promoting a culture of safety and quality, healthcare facilities can enhance their reputation and attract more patients. Moreover, improved pharmacovigilance practices can help to reduce healthcare costs by minimizing the impact of ADRs on patient outcomes. In summary, pharmacovigilance training programs offer numerous benefits for healthcare professionals in developing countries, including improved knowledge and skills, increased confidence, better patient care, and improved institutional performance.

Factors affecting the health professionals' knowledge, attitudes, and practices

Pharmacovigilance, the science of detecting, assessing, and preventing adverse effects of drugs, plays a crucial role in ensuring the safety and efficacy of drugs. It is an essential aspect of healthcare that requires continuous monitoring and evaluation of drugs' safety profile. Healthcare professionals, including physicians, pharmacists, and nurses, are primarily responsible for detecting, assessing, and reporting adverse drug reactions (ADRs) to pharmacovigilance centers.

Healthcare professionals' education and training in pharmacovigilance are essential to ensure better knowledge, attitudes, and practices related to pharmacovigilance. Healthcare professionals with extensive education and training in pharmacovigilance are more likely to identify and report ADRs accurately. They possess a better understanding of the importance of pharmacovigilance, the pharmacovigilance system, and the reporting process. In addition, they are aware of the possible consequences of underreporting ADRs and the significance of pharmacovigilance for public health.

The education and training of healthcare professionals in pharmacovigilance can have a significant impact on patient safety. A well-trained healthcare professional can effectively detect and report ADRs, which can lead to the timely identification of safety signals and the withdrawal of unsafe drugs from the market. Furthermore, healthcare professionals with extensive education and training in pharmacovigilance can also educate patients about the importance of reporting ADRs, which can increase patient participation in the pharmacovigilance process.

Education and training are crucial components of pharmacovigilance. Healthcare professionals with more extensive education and training in pharmacovigilance are likely to have better knowledge, attitudes, and practices related to pharmacovigilance. Their education and training can enhance patient safety by improving the identification and reporting of ADRs, leading to the timely detection of safety signals and the withdrawal of unsafe drugs from the market. Therefore, it is important to ensure that healthcare professionals receive appropriate education and training in pharmacovigilance to improve patient safety and public health.

Pharmacovigilance is a vital aspect of drug safety, which relies on healthcare professionals to detect and report adverse drug reactions (ADRs). The availability and accessibility of pharmacovigilance information, such as ADR reporting forms and guidelines, can significantly impact healthcare professionals' knowledge and practices related to pharmacovigilance.

Access to pharmacovigilance information is crucial for healthcare professionals to understand the importance of pharmacovigilance and its reporting process. The availability of clear and concise ADR reporting forms can assist healthcare professionals in accurately identifying and reporting ADRs. Moreover, accessible guidelines can provide step-by-step instructions on how to report ADRs, ensuring the completeness and quality of the reports.

Furthermore, the availability of pharmacovigilance information can have a positive impact on healthcare professionals' attitudes and practices related to pharmacovigilance. Accessible and user-friendly pharmacovigilance information can motivate healthcare professionals to report ADRs, thereby increasing the reporting rate. This, in turn, can improve the detection and evaluation of drug safety signals, leading to the timely withdrawal of unsafe drugs from the market and improved patient safety.

The lack of access to pharmacovigilance information can result in inadequate knowledge and practices related to pharmacovigilance. Healthcare professionals may lack the necessary skills and knowledge to identify and report ADRs accurately. Additionally, the absence of clear reporting forms and guidelines can lead to incomplete and inaccurate reporting of ADRs, resulting in delayed detection of drug safety signals and potential harm to patients.

Access to pharmacovigilance information is crucial to ensure adequate knowledge and practices related to pharmacovigilance. The availability and accessibility of ADR reporting forms and guidelines can assist healthcare professionals in accurately identifying and reporting ADRs, resulting in improved patient safety. Therefore, it is essential to ensure that healthcare professionals have easy access to clear and concise pharmacovigilance information to improve the detection and evaluation of drug safety signals and enhance patient safety.

Healthcare professionals play a critical role in pharmacovigilance, which involves the detection, assessment, and prevention of adverse drug reactions (ADRs). However, their perception of ADRs can significantly impact their attitudes towards pharmacovigilance. If they view ADRs as a rare or insignificant occurrence, they may not prioritize reporting them, resulting in underreporting of ADRs and delayed detection of drug safety signals.

Healthcare professionals' perception of ADRs can be influenced by various factors, such as their training, experience, and knowledge of drug safety. Healthcare professionals who perceive ADRs as a rare occurrence may not report them as they do not consider them significant. Additionally, healthcare professionals may not report ADRs if they perceive the severity of the ADR to be low, leading to underreporting of ADRs.

Furthermore, healthcare professionals' attitudes towards ADRs can also influence their reporting behavior. If healthcare professionals perceive ADR reporting as time-consuming or believe that they lack the necessary skills to report ADRs accurately, they may not prioritize reporting ADRs. Moreover, healthcare professionals may not report ADRs if they fear potential negative consequences, such as legal liability or damage to their reputation.

In contrast, healthcare professionals who perceive ADRs as significant occurrences and understand the importance of pharmacovigilance are more likely to report ADRs accurately. These healthcare professionals may have a positive attitude towards ADR reporting and view it as an essential aspect of patient safety.

Healthcare professionals' perception of ADRs can significantly impact their attitudes towards pharmacovigilance. Perceiving ADRs as a rare or insignificant occurrence can lead to underreporting of ADRs and delayed detection of drug safety signals. Therefore, it is essential to ensure that healthcare professionals understand the significance of ADRs and the importance of

reporting them to improve patient safety. Healthcare professionals should receive adequate training and education on pharmacovigilance to increase their knowledge, skills, and attitudes towards ADR reporting.

However, their workload and time constraints can significantly impact their ability to report ADRs and engage in pharmacovigilance activities.

Healthcare professionals often work in fast-paced and high-pressure environments, leaving them with limited time to engage in pharmacovigilance activities. They may prioritize other tasks, such as patient care, over ADR reporting, resulting in delayed or inadequate reporting of ADRs. This can lead to underreporting of ADRs and delayed detection of drug safety signals, potentially putting patients at risk.

Moreover, healthcare professionals' workload can also impact their ability to identify ADRs accurately. They may not have enough time to monitor patients for ADRs or to collect relevant information necessary for reporting. This can lead to incomplete or inaccurate reporting of ADRs, compromising the quality of the data available for drug safety evaluation.

Furthermore, healthcare professionals may face time constraints when it comes to receiving adequate training and education on pharmacovigilance. Lack of training and education can result in inadequate knowledge and skills necessary for accurate ADR reporting, leading to underreporting of ADRs.

Healthcare professionals' workload and time constraints can significantly impact their ability to engage in pharmacovigilance activities. Healthcare professionals must receive adequate support and resources to facilitate ADR reporting and drug safety evaluation. This may involve prioritizing pharmacovigilance activities, providing adequate training and education on pharmacovigilance, and investing in resources such as ADR reporting tools and software. Adequate support and resources can help healthcare professionals to identify and report ADRs accurately, ultimately improving patient safety.

Organizational support and leadership play a crucial role in facilitating healthcare professionals' engagement in pharmacovigilance activities. If an organization prioritizes pharmacovigilance and provides support for reporting ADRs, healthcare professionals are more likely to engage in pharmacovigilance activities.

Organizations can provide support for pharmacovigilance activities by investing in resources such as ADR reporting tools and software, providing training and education on pharmacovigilance, and promoting a culture of safety that encourages ADR reporting. Organizations can also establish clear reporting policies and procedures that simplify the ADR reporting process, making it easier for healthcare professionals to report ADRs.

Moreover, leadership within an organization can also influence healthcare professionals' attitudes towards pharmacovigilance. If leaders prioritize pharmacovigilance and actively promote ADR reporting, healthcare professionals are more likely to engage in pharmacovigilance activities. Leaders can also model the desired behavior by reporting ADRs themselves, which can help to reinforce the importance of ADR reporting among healthcare professionals.

Organizational support can also help to address time constraints and workload issues that may impact healthcare professionals' engagement in pharmacovigilance activities. By providing resources and support for pharmacovigilance activities, organizations can help to streamline the ADR reporting process, reducing the burden on healthcare professionals.

Organizational support and leadership play a crucial role in facilitating healthcare professionals' engagement in pharmacovigilance activities. Organizations that prioritize pharmacovigilance and provide support for ADR reporting can help to create a culture of safety that encourages healthcare professionals to engage in pharmacovigilance activities. By investing in resources and support for pharmacovigilance activities, organizations can help to address time constraints and workload issues that may impact healthcare professionals' engagement in pharmacovigilance activities. Ultimately, this can lead to improved patient safety and better detection and prevention of ADRs.

Healthcare professionals' fear of legal consequences, such as lawsuits or disciplinary action, can significantly impact their willingness to report ADRs. While healthcare professionals are obligated to report ADRs, fear of legal consequences can create a significant barrier to ADR reporting.

One of the primary reasons healthcare professionals may fear legal consequences is the possibility of being sued for malpractice. Healthcare professionals may worry that reporting ADRs will create a legal record that can be used against them in the future. This fear can result in underreporting of ADRs and a delay in detecting drug safety signals, putting patients at risk.

Additionally, healthcare professionals may fear disciplinary action or negative consequences from their employers for reporting ADRs. They may worry that their employer will view ADR reporting as a negative reflection on their practice or that they may face repercussions for reporting ADRs. This fear can lead to underreporting of ADRs and a reluctance to engage in pharmacovigilance activities.

Moreover, healthcare professionals may also fear that reporting ADRs may damage their reputation or affect their ability to secure future employment. This fear can result in underreporting of ADRs, compromising the quality of the data available for drug safety evaluation.

To address the fear of legal consequences, healthcare professionals must be provided with clear guidance and support regarding the ADR reporting process. This can involve providing legal protection for healthcare professionals who report ADRs in good faith and establishing clear reporting policies and procedures that simplify the ADR reporting process. Additionally, organizations must create a culture of safety that encourages ADR reporting and provides support for healthcare professionals who report ADRs.

Healthcare professionals' fear of legal consequences can create a significant barrier to ADR reporting. To address this fear, healthcare professionals must be provided with clear guidance and support, and organizations must create a culture of safety that encourages ADR reporting. By addressing the fear of legal consequences, healthcare professionals can engage in pharmacovigilance activities without fear of negative consequences, ultimately improving patient safety.

In some settings, healthcare professionals may face language barriers that prevent them from accessing pharmacovigilance information in their native language, which can significantly impact their ability to engage in pharmacovigilance activities.

Language barriers can create significant challenges for healthcare professionals who may struggle to understand pharmacovigilance guidelines or reporting forms. This can lead to underreporting of ADRs and a delay in the detection of drug safety signals, putting patients at risk.

Moreover, language barriers can also impact healthcare professionals' ability to communicate effectively with their patients, making it challenging to obtain accurate information regarding ADRs. Healthcare professionals may struggle to communicate the potential risks and benefits of medication to their patients, leading to suboptimal treatment decisions.

To address language barriers, healthcare organizations must invest in resources that provide healthcare professionals with access to pharmacovigilance information in their native language. This can involve translating pharmacovigilance guidelines, reporting forms, and educational resources into multiple languages, ensuring that healthcare professionals have access to information that they can understand.

Moreover, healthcare organizations must prioritize language diversity when recruiting healthcare professionals. This can involve hiring healthcare professionals who speak multiple languages, ensuring that patients have access to healthcare professionals who can communicate effectively with them.

Language barriers can significantly impact healthcare professionals' ability to engage in pharmacovigilance activities, leading to underreporting of ADRs and a delay in detecting drug safety signals. To address this issue, healthcare organizations must invest in resources that provide healthcare professionals with access to pharmacovigilance information in their native language and prioritize language diversity when recruiting healthcare professionals. By addressing language barriers, healthcare organizations can ensure that all patients receive safe and effective medication treatment.

Model

In a multiple regression analysis, we assume that the dependent variable is a linear composite of many independent ones. Here's how we may characterize the model [13]–[15]:

if x_{nj} is the j^{th} predictor for observation n:

$$y_n = \beta_0 + \beta_1 x_{n1} + \cdots + \beta_D x_{nD} + \epsilon_n.$$

More simply, this might be stated as

$$y_n = \boldsymbol{\beta}^\top \mathbf{x}_n + \epsilon_n.$$

The minimization of this loss function is simplified by working with matrices rather than sums. Define y and X with:

$$\mathbf{y} = \begin{bmatrix} y_1 \\ \dots \\ y_N \end{bmatrix} \in \mathbb{R}^N, \quad \mathbf{X} = \begin{bmatrix} \mathbf{x}_1^\top \\ \dots \\ \mathbf{x}_N^\top \end{bmatrix} \in \mathbb{R}^{N \times (D+1)},$$

For example, the loss function may be expressed as:

$$\mathcal{L}(\hat{\boldsymbol{\beta}}) = \frac{1}{2}(\mathbf{y} - \mathbf{X}\hat{\boldsymbol{\beta}})^\top (\mathbf{y} - \mathbf{X}\hat{\boldsymbol{\beta}}).$$

In order to test the assumptions, we used the following multivariate regression model:

$$KAP_i = \alpha + \beta_1 Edu_i + \beta_2 Info_i + \beta_3 PADR_i + \beta_4 Tconst_i + \beta_5 Org_i + \beta_6 Legal_i + \beta_7 Language_i + \varepsilon_i$$

The details of the variables are given in table 1. The dependent variable *KAP* denotes the knowledge, attitudes, and practices of the healthcare professionals about pharmacovigilance.

Table 1. Factors affecting healthcare professionals' knowledge, attitudes, and practices related to pharmacovigilance

Factor	Symbol	Impact
Education and training	E&T	Healthcare professionals with more extensive education and training are likely to have better knowledge
Access to information	A&I	Availability and accessibility of pharmacovigilance information can impact knowledge and practices
Perception of ADRs	P-ADR	Perception of ADRs can influence attitudes towards pharmacovigilance
Time constraints	T-const	Workload and time constraints can impact ability to report ADRs and engage in pharmacovigilance
Organizational support	Org-sup	Organizational support and leadership can influence attitudes towards pharmacovigilance
Fear of legal consequences	F-LC	Fear of legal consequences can impact willingness to report ADRs
Language barriers	L-bar	Lack of access to information in native language can impact knowledge and practices

Table 2. Regression results

Dependent Variable: KAP
Method: Least Squares
Sample: 1 285
Included observations: 285

Variable	Coefficient	Std. Error	t-Statistic	Prob.
EDU	0.874779	0.059665	14.66146	0.0000
INFO	1.068069	0.060242	17.72956	0.0000
ORG	1.046891	0.058748	17.82016	0.0000
PADR	1.095735	0.057475	19.06468	0.0000
TCONST	1.025621	0.059863	17.13286	0.0000
LANGUAGE	0.068598	0.060566	1.132624	0.2584
LEGAL	0.049536	0.056742	0.873008	0.3834
C	0.382384	0.075348	5.074925	0.0000

R-squared	0.855711	Mean dependent var	3.027218
Adjusted R-squared	0.852065	S.D. dependent var	0.740671
S.E. of regression	0.284879	Akaike info criterion	0.354167
Sum squared resid	22.48028	Schwarz criterion	0.456693
Log likelihood	-42.46873	Hannan-Quinn criter.	0.395267
F-statistic	234.6801	Durbin-Watson stat	1.834067
Prob(F-statistic)	0.000000		

Results

Figure 1. scatter plot among the factors.



The results show the output of a linear regression model with KAP (dependent variable) and six independent variables: EDU, INFO, ORG, PADR, TCONST, LANGUAGE, and LEGAL. The constant term is also included in the model as C. The coefficient for each independent variable represents the change in the dependent variable (KAP) associated with a one-unit increase in the corresponding independent variable, holding all other independent variables constant. The p-value for each independent variable represents the statistical significance of the coefficient. A p-value less than the commonly used threshold of 0.05 indicates that the coefficient is statistically significant at the 95% confidence level.

Based on the results, all independent variables except for LEGAL and LANGUAGE are statistically significant in predicting KAP. The coefficient values suggest that higher levels of EDU, INFO, ORG, PADR, and TCONST are associated with higher levels of KAP. The coefficient for the constant term (C) indicates that there is a baseline level of KAP that is not explained by any of the independent variables included in the model.

However, the coefficient for LANGUAGE is not statistically significant at the 95% confidence level, which means that there is insufficient evidence to suggest that this variable has a significant impact on KAP. Similarly, the coefficient for LEGAL is also not statistically significant.

The R-squared value of 0.855711 indicates that 85.57% of the variation in the dependent variable (KAP) can be explained by the independent variables included in the model. This suggests that the model provides a good fit to the data and has a high degree of explanatory power.

The adjusted R-squared value of 0.852065 is similar to the R-squared value, but takes into account the number of independent variables in the model. This value suggests that the independent variables explain a significant amount of the variation in KAP, even after accounting for the number of independent variables in the model.

The mean of the dependent variable is 3.027218, which indicates that, on average, the KAP score is close to 3.

The standard deviation of the dependent variable is 0.740671, which suggests that the KAP scores have a relatively narrow spread around the mean.

The standard error of regression (0.284879) represents the average distance that the actual values of KAP are from the predicted values based on the model.

The F-statistic of 234.6801 with a p-value of 0.000000 indicates that the model as a whole is statistically significant, meaning that at least one of the independent variables in the model is significantly related to the dependent variable.

The Durbin-Watson statistic of 1.834067 is used to detect the presence of autocorrelation in the residuals of the model. A value close to 2 suggests no autocorrelation, while values significantly less than 2 suggest positive autocorrelation and values significantly greater than 2 suggest negative autocorrelation. In this case, the value of 1.834067 suggests that there is no significant autocorrelation in the residuals.

The Akaike information criterion (AIC), Schwarz criterion (SC), and Hannan-Quinn criterion (HQC) are measures of the relative quality of different statistical models for a given dataset. Lower values of AIC, SC, and HQC indicate a better fit. In this case, the AIC value of 0.354167, SC value of 0.456693, and HQC value of 0.395267 suggest that the current model is the best fit among the alternative models that could have been considered.

Conclusion

Pharmacovigilance is an essential aspect of ensuring patient safety and the rational use of medication. However, despite its importance, pharmacovigilance is still underdeveloped in many regions, including the Middle East and North Africa (MENA) region. To ensure that patients receive safe and effective medication treatment, policymakers, healthcare organizations, and other stakeholders must prioritize pharmacovigilance training programs in the MENA region and beyond.

The MENA region faces significant challenges when it comes to pharmacovigilance. The region has a high burden of disease and limited resources, making it challenging to prioritize pharmacovigilance activities. Additionally, there is a lack of awareness among healthcare professionals regarding the importance of pharmacovigilance and the role they play in ensuring patient safety.

To address these challenges, policymakers, healthcare organizations, and other stakeholders must prioritize pharmacovigilance training programs in the MENA region. These programs must aim to improve healthcare professionals' knowledge, attitudes, and practices related to pharmacovigilance, ensuring that they have the skills and resources necessary to engage in pharmacovigilance activities effectively.

One of the primary benefits of pharmacovigilance training programs is that they can improve healthcare professionals' knowledge regarding drug safety and ADR reporting. This can involve educating healthcare professionals regarding the importance of pharmacovigilance, the types of ADRs they may encounter, and how to report ADRs effectively. By improving healthcare professionals' knowledge regarding pharmacovigilance, they can take a more active role in ensuring patient safety and the rational use of medication.

Additionally, pharmacovigilance training programs can improve healthcare professionals' attitudes towards pharmacovigilance. Healthcare professionals may view pharmacovigilance as a time-consuming and burdensome activity, leading to underreporting of ADRs. However, by providing healthcare professionals with the necessary training and resources, they may view pharmacovigilance as a critical aspect of their practice, leading to increased engagement in pharmacovigilance activities.

Furthermore, pharmacovigilance training programs can improve healthcare professionals' practices related to pharmacovigilance. This can involve providing healthcare professionals with the necessary resources and support to engage in pharmacovigilance activities effectively. For example, pharmacovigilance training programs can provide healthcare professionals with access to reporting forms and guidelines, simplifying the ADR reporting process.

To ensure the success of pharmacovigilance training programs, policymakers, healthcare organizations, and other stakeholders must work together to develop comprehensive training programs that meet the unique needs of healthcare professionals in the MENA region. This can involve conducting needs assessments to identify healthcare professionals' knowledge gaps and developing training programs that address these gaps [16], [17].

Moreover, healthcare organizations must prioritize pharmacovigilance training programs as part of their ongoing professional development activities. This can involve providing healthcare professionals with regular training sessions, ensuring that they stay up to date with the latest pharmacovigilance guidelines and best practices. Furthermore, policymakers must provide funding and resources to support the development and implementation of pharmacovigilance training programs. This can involve investing in educational resources, providing financial incentives for

healthcare professionals who engage in pharmacovigilance activities, and creating regulatory frameworks that prioritize patient safety [18], [19].

In addition to the MENA region, pharmacovigilance training programs must also be prioritized in other regions with limited pharmacovigilance infrastructure. For example, in low- and middle-income countries (LMICs), pharmacovigilance infrastructure is often underdeveloped, leading to underreporting of ADRs and a delay in detecting drug safety signals.

To address these challenges, policymakers, healthcare organizations, and other stakeholders must prioritize pharmacovigilance training programs in LMICs, ensuring that healthcare professionals have the necessary skills and resources to engage in pharmacovigilance activities effectively. This can involve partnering with international organizations, such as the World Health Organization, to develop comprehensive training programs that meet the unique needs of healthcare professionals in LMICs.

Moreover, pharmacovigilance training programs must be integrated into the broader healthcare system, ensuring that pharmacovigilance is viewed as a critical aspect of patient safety and the rational use of medication. This can involve creating a culture of reporting and encouraging healthcare professionals to report ADRs by providing them with the necessary resources and support.

Furthermore, pharmacovigilance training programs must prioritize the involvement of patients in pharmacovigilance activities. Patients are an essential source of information regarding ADRs, and involving them in pharmacovigilance activities can help improve drug safety and the rational use of medication. For example, patients can be encouraged to report ADRs directly to pharmacovigilance authorities or healthcare professionals, providing valuable information regarding drug safety signals.

Pharmacovigilance training programs are essential to ensuring patient safety and the rational use of medication. Policymakers, healthcare organizations, and other stakeholders must prioritize the development and implementation of pharmacovigilance training programs in the MENA region and beyond, ensuring that healthcare professionals have the necessary skills and resources to engage in pharmacovigilance activities effectively. By doing so, we can improve drug safety, reduce the burden of disease, and ensure that patients receive safe and effective medication treatment.

References

[1] J. E. Campbell, M. Gossell-Williams, and M. G. Lee, “A Review of Pharmacovigilance,” *West Indian Med. J.*, vol. 63, no. 7, pp. 771–774, Dec. 2014.
[2] W. Health Organization, “The importance of pharmacovigilance,” 2002. [Online]. Available: https://apps.who.int/iris/bitstream/handle/10665/42493/a75646.pdf.
[3] M. A. Veronin, R. Dixit, and R. P. Schumaker, “A Decision Tree Analysis of Opioid and Prescription Drug Interactions Leading to Death Using the FAERS Database,” in *IIMA/ICITED Joint Conference 2018*, 2018, pp. 67–67.
[4] M. A. Veronin, R. P. Schumaker, and R. R. Dixit, “A systematic approach to’cleaning’of drug name records data in the FAERS database: a case report,” *Journal of Big …*, 2020.
[5] P. Dhake, R. Dixit, and D. Manson, “Calculating a Severity Score of an Adverse Drug Event Using Machine Learning on the FAERS Database,” *IIMA/ICITED UWS*, 2017.
[6] R. H. Meyboom, A. C. Egberts, F. W. Gribnau, and Y. A. Hekster, “Pharmacovigilance in perspective,” *Drug Saf.*, vol. 21, no. 6, pp. 429–447, Dec. 1999.

[7] A. M. Ahmed, I. M. Izham, and P. Subish, "Importance of consumer pharmacovigilance system in developing countries: a case of Malaysia," *J. Clin. Diagn. Res.*, 2010.
[8] Z. Ma *et al.*, "Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database," *Front. Pharmacol.*, vol. 12, 2021.
[9] D. Thomas and S. Zachariah, "Chapter 11 - Knowledge, Attitude, and Practice of Pharmacovigilance in Developing Countries," in *Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries*, M. I. M. Ibrahim, A. I. Wertheimer, and Z.-U.-D. Babar, Eds. Academic Press, 2018, pp. 177–193.
[10] A. O. Isah, S. N. Pal, S. Olsson, and A. Dodoo, "Specific features of medicines safety and pharmacovigilance in Africa," *Adv. Drug Res.*, 2012.
[11] P. Dhake, R. Dixit, D. Manson, R. Schumaker, and M. Veronin, "Calculating a Severity Score of an Adverse Drug Event Using Machine Learning on the FAERS Database," in *IIMA/ICITED UWS Joint Conference*, 2017, pp. 20–30.
[12] M. A. Veronin, R. P. Schumaker, and R. Dixit, "The Irony of MedWatch and the FAERS Database: An Assessment of Data Input Errors and Potential Consequences," *J. Pharm. Technol.*, vol. 36, no. 4, pp. 164–167, Aug. 2020.
[13] J. Salah, "Riemann Hypothesis Holds virtually true," Nov-2021.
[14] H. U. Rehman, M. Darus, and J. Salah, "A note on Caputo's derivative operator interpretation in economy," *J. Appl. Math.*, 2018.
[15] J. Salah, "A note on the modified Caputo's fractional calculus derivative operator," *Far East J. Math. Sci. ,* vol. 100, no. 4, pp. 609–615, Sep. 2016.
[16] A. M. Hughes *et al.*, "Saving lives: A meta-analysis of team training in healthcare," *J. Appl. Psychol.*, vol. 101, no. 9, pp. 1266–1304, Sep. 2016.
[17] B. Gross *et al.*, "Crew resource management training in healthcare: a systematic review of intervention design, training conditions and evaluation," *BMJ Open*, vol. 9, no. 2, p. e025247, Mar. 2019.
[18] P. Paal, Y. Helo, and E. Frick, "Spiritual Care Training Provided to Healthcare Professionals: A Systematic Review," *J. Pastoral Care Counsel.*, vol. 69, no. 1, pp. 19–30, Mar. 2015.
[19] T. D. Probst and K. Kasztelnik, "The observational research study with the trends in healthcare training and leadership ethics in the United States," *Bus. Ethics Lead.*., vol. 3, no. 4, pp. 6–24, 2020.